

Breast Disease-Oriented Team

Clinical Research Treatment Trial Flowchart
CRC Contact: GRP - CTU Breast Coordinators (CTUBreastCRC@hs.uci.edu)
Clinical Research Manager: Juan Miranda



ALL

UCI 24-05

Riluzole PO vs. Placebo PO
Perceived worsening of *cognitive function*

BREAST COHORT FULL

PI: Chan

CRC: Randy Kang

Accrual: 24/39



HER2+

HER2-

SWOG S2206 (HER2-/low/equivocal)
Arm 1: SOC AC-T
Arm 2: SOC AC-T + Durvalumab (IgG1k mAb)
MammaPrint Index Score MP2 required

PI: Parajuli
CRC: Madeleine Phan
Accrual: 4/10

UCI 25-48
Riluzole PO vs. Placebo PO
Perceived worsening of cognitive function

PI: Chan
CRC: Madeleine Phan
Accrual: 0/20



Adjuvant Therapy – HER2-

HR+

UCI 25-106
 BMS-986517 Monotherapy
 HR+/Her2- and TNBC

PI: Dr. Nabar
 Coord: N. Arechiga/TBD
 Accrual: 0/5

ER+

A012301 (LoTam)
 Low Dose Tamoxifen Vs SOC endocrine therapy for Low risk (defined in notes)

PI: Parajuli
 CRC: Juan Miranda
 Accrual: 15/30

NRG BR007
 Arm 1: RT + ET
 Arm 2: ET
 Oncotype-DX Recurrence Score \leq 18 (unless T1a tumor) required

PI: Mehta
 CRC: Stephany Ruiz
 Accrual: 3/5

UCI 23-192 (WIDER)
 Ribociclib 400mg + SOC ET + Goserelin or Leuprolide
 Exploratory cohort is same treatment

PI: Parajuli
 CRC: Stephany Ruiz
 Accrual: 2/5

UCI 24-116 (ELEGANT)
 Arm A: Elacestrant PO (SERD)
 Arm B: Physician's choice endocrine Tx

PI: Parajuli
 CRC: Juan Miranda
 Accrual: 0/5



HER2+

A012303 (Any HR)

Arm 1: Trastuzumab +/- Pertuzumab every 3wks for 12months

Arm 2: Trastuzumab +/- Pertuzumab every 3wks for 12months

PI: Lavasani
CRC: Randy Kang
Accrual: 0/5

TNBC

UCI 25-106

BMS-986517 Monotherapy
HR+/Her2- and TNBC

PI: Dr. Nabar
Coord: N. Arechiga/TBD
Accrual: 0/5



2L+

UCI 19-145 (HR+/HER2-)
CDK 4/6 inhibitor+ER Regulator+Aromatase Inhibitor
CRCs: Stephany Ruiz, Michael Rodriguez, Madeleine Phan
Accrual: 21/40

2L+

UCI 22-09 (TNBC, HR+/HER2-)
XMT-1660 (ADC) – BC, EC, OC, ACC-I
Dose Esc, Backfill Cohort, Exp
SLOT RSVP REQ (HR+/TNBC COHORT TEMP CLOSED)
PI: Parajuli
CRC: Juan Miranda
Accrual: 7/10



2L+

Metastatic: HER2 Low, HER2+

**UCI 24-49 (HER2+ IHC 2-3+,
HER2 Amp ISH)**

Dose Esc (Ph Ib):

Cohort A: Zongertinib (BI 1810631; HER2 inhibitor) + T-DM1
Cohort B: BI 1810631 + T-DXd
Cohort K:
Zongertinib+Trastuzumab

SLOT RSVP REQ (Dose Esc)

PI: Dayyani
CRC: Randy Kang
Accrual: 3/10

UCI 23-109 (HER2 IHC ≥1+)

Cohort A: HER2-Low: Disitamab Vedotin (ADC) vs. DV + Tucatinib
Cohort B: HER2+: DV vs. DV + Tucatinib

SLOT RSVP REQ (Dose Esc)

PI: Dr. Parajuli

CRC: My Nguyen; Breast CRC TBD
Accrual: 2/10

UCI 25-81/UCI 25-81-03 (HER2+)

*Locally adv or Mets HER2+ prior T-DXd relapsed in 6month
Physician Choice then either Cohort 1 or 2*

Cohort 1: Evorpcept (ALX148)+Trastuzumab+Chemo

Cohort 2: Trastuzumab+Chemo

PI: Parajuli
CRC: TBD
Accrual: 0/5



METASTATIC: 1L+

UCI 22-09 (TNBC, HR+/HER2-)

XMT-1660 (ADC) – BC, EC, OC, ACC-I

Dose Esc, Backfill Cohort, Exp

SLOT RSVP REQ (HR+/TNBC COHORT TEMP CLOSED)

PI: Parajuli

CRC: Juan Miranda

Accrual: 6/10

ETCTN 10546

ASTX727 (Cytidine deaminase (CDA) inhibitor + nucleoside hypomethylating agent (HMA)) + Paclitaxel +

Pembrolizumab

DL-2 now open for TNBC

SLOT RSVP REQ

PI: Parajuli

CRC: Randy Kang

Accrual: 1/5

UCI 24-08

SPEDOX-6 IV

SLOT RSVP REQ

PI: Chow

CRC: Erin Torrison; Breast CRC TBD

Accrual: 6/67

UCI 24-195

PF-08046054 (an ADC) monotherapy

Dose ESC (Part A) or Schedule Optimization (Part B):

PD-L1 expression ≥ 1 TPS, CPS, or % IC

Signal-seeking cohort: ADC monotherapy

Biology cohort: ADC monotherapy

PI: Nagasaka

CRC: TBD

Accrual: 0/6

METASTATIC: 1L+



ALL

UCI 24-197

TNG456 Monotherapy or Combined w/Abemaciclib in solid tumors with MTAP Loss

SLOT RSVP REQ

CRC: TBD

PI: Park

Accrual: 0/5

UCI 24-142

Phase 1 Dose Esc

Group A: VET3-TGI monotherapy by ITu injection

Group C: VET3-TGI monotherapy by IV infusion

Group B: VET3-TGI by ITu injection, Group D: VET3-TGI IV infusion combo with pembrolizumab

SLOT RSVP REQ

PI: Uchio

CRC: TBD

Accrual: 0/4



ALL

UCI 22-26

CB-03-10 (PO; AR and GR antagonist)
 Part 1 (esc): adv/met solid tumor
 Part 2 (exp): adv/met solid tumor or relapsed/refractory
 TNBC

SLOT RSVP REQ

HPB/Panc CRC: Miranda Duron
 Breast CRC: TBD

PI: Dayyani
 Accrual: 11/12

UCI 25-75

CRN09682 IV (an MMAE) for SST2-expressing solid tumors

CRC: TBD

PI: Dayyani
 Accrual: 0/15

NRG CC014

SOC vs SOC + RT for High-risk Asymptomatic Bone
 Metastases

SLOT RSVP REQ

PI: Harris
 CRC: Natalie Arechiga; Breast CRC TBD
 Accrual: 4/10

NRG CC015

E-Mindfulness for living after Breast cancer

PI: Kim
 CRC: TBD
 Accrual: 0/10



Other Interventional/LTFU

UCI 25-43

Type 1 Hybrid Effectiveness of a Patient-Reported Outcomes

PI: Chan
CRC: TBD
Accrual: 0/5

UCI 24-87

Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Patients with Solid Tumors

PI: Arter
CRC: TBD
Accrual: 0/5



BASIC SCIENCE

UCI 18-136
6 slots for Cohort 1/neo-adjuvant and 13 slots for Cohort 2/adjuvant
PI: Parajuli
CRC: Caylee Carlton
Accrual: 79/100

UCI 17-05 (BRCA1 -/-, +/+)

PI: Parajuli
CRC: Billy Joel Sanchez
Accrual: 49/75

Alliance A232403
DOT Approved
Financial Hardship study
PI: Lavasani
CRC: TBD
Accrual: 0/5

SUPPORTIVE CARE

UCI 24-64
High fiber diet as therapy response and reduce recurrence

PI: Whiteson
CRC: TBD
Accrual: 0/60

UCI 25-83
Mobile Health Intervention to Improve Adherence to Oral Anticancer Therapy
PI: Sadigh
CRC: TBD
Accrual: 8/30

UCI 25-115
Couples Intervention for Young Adult Cancer Survivors: A Pilot Study
PI: Hoyt
CRC: TBD
Accrual: 0/5



HEALTH SERVICES RESEARCH

UCI 25-25

PI: Eakin
CRC: TBD
Accrual: 0/150

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended